Skip to main content
Erschienen in: Digestive Diseases and Sciences 8/2023

03.06.2023 | Brief Report

Correlations Between Gastrointestinal Symptoms and Endoscopic–Histologic Disease Activity in Adults with Ulcerative Colitis

verfasst von: Chung Sang Tse, Hang P. Nguyen, Siddharth Singh, Parambir S. Dulai, Jennifer Neill, Helen Le, Mark Valasek, Thierry Dervieux, Angelina E. Collins, Brigid Sweeney Boland

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Discordance between gastrointestinal (GI) symptoms and endoscopic inflammation in patients with ulcerative colitis (UC) is known. However, the correlations between symptoms and endoscopic and histologic (endo-histologic) mucosal healing and remains unknown.

Methods

We performed a secondary analysis of prospectively collected clinical, endoscopic, and histologic data on 254 colonoscopies from 179 unique adults at a tertiary referral center from 2014 to 2021. Spearman’s rank was used to assess the correlation between patient reported outcomes and objective assessments of disease activity, as measured by validated instruments: Two-item patient-reported outcome measure (PRO-2) for stool frequency and rectal bleeding, the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) for endoscopic inflammation, and the Geboes score for histologic inflammation. The predictive value of objective assessments of inflammation and clinical symptoms was described using sensitivity, specificity, and positive/negative predictive value.

Results

One-quarter (28%, 72/254) of cases were in endo-histologic remission; of these, 25% (18/72) report GI symptoms (22% diarrhea; 6% rectal bleeding). Endo-histologically active disease had higher sensitivity (95% rectal bleeding; 87% diarrhea) and negative predictive value (94% rectal bleeding, 78% diarrhea) for clinically active disease compared to active disease on endoscopic (77%) or histologic assessment only (80%). The specificity of endo/histologic inflammation for GI symptoms was < 65%. PRO-2 was positively correlated with endoscopic disease activity (Spearman’s rank 0.57, 95% CI 0.54–0.60, p < 0.0001) and histologic disease activity (Spearman’s rank 0.49, 0.45–0.53, p < 0.0001).

Conclusion

One-quarter of patients with ulcerative colitis in endo-histologic (deep) remission have gastrointestinal symptoms, more commonly with diarrhea than rectal bleeding. Endo-histologic inflammation has high sensitivity (≥ 87%) for diarrhea/rectal bleeding.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Narula N, Alshahrani AA, Yuan Y, Reinisch W, Colombel JF. Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2019;17:411–418.CrossRefPubMed Narula N, Alshahrani AA, Yuan Y, Reinisch W, Colombel JF. Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2019;17:411–418.CrossRefPubMed
2.
Zurück zum Zitat Ma C, Sandborn WJ, D’Haens GR et al. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020;18:1760-1768.e1761.CrossRefPubMed Ma C, Sandborn WJ, D’Haens GR et al. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020;18:1760-1768.e1761.CrossRefPubMed
3.
Zurück zum Zitat Colombel JF, Keir ME, Scherl A et al. Discrepancies Between Patient-Reported Outcomes, and Endoscopic and Histological Appearance in UC. Gut. 2017;66:2063–2068.CrossRefPubMed Colombel JF, Keir ME, Scherl A et al. Discrepancies Between Patient-Reported Outcomes, and Endoscopic and Histological Appearance in UC. Gut. 2017;66:2063–2068.CrossRefPubMed
4.
Zurück zum Zitat Sedano R, Hogan M, Zou G et al. Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials. Inflammatory Bowel Diseases. 2022;20:324–327. Sedano R, Hogan M, Zou G et al. Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials. Inflammatory Bowel Diseases. 2022;20:324–327.
5.
Zurück zum Zitat Turner D, Ricciuto A, Lewis A et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160:1570–1583.CrossRefPubMed Turner D, Ricciuto A, Lewis A et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160:1570–1583.CrossRefPubMed
6.
Zurück zum Zitat Food and Drug Administration. Developing Drugs for Treatment Guidance for Industry: Draft Guidance. In: Services USDoH, Human, eds. Silver Spring, M: Food and Drug Administration; 2022. Food and Drug Administration. Developing Drugs for Treatment Guidance for Industry: Draft Guidance. In: Services USDoH, Human, eds. Silver Spring, M: Food and Drug Administration; 2022.
7.
Zurück zum Zitat Satsangi J, Silverberg MS, Vermeire S, Colombel J-F. The Montreal Classification of Inflammatory Bowel Disease: Controversies, Consensus, and Implications. Gut. 2006;55:749–753.CrossRefPubMedPubMedCentral Satsangi J, Silverberg MS, Vermeire S, Colombel J-F. The Montreal Classification of Inflammatory Bowel Disease: Controversies, Consensus, and Implications. Gut. 2006;55:749–753.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Jairath V, Khanna R, Zou GY et al. Development of Interim Patient-Reported Outcome Measures for the Assessment of Ulcerative Colitis Disease Activity in Clinical Trials. Aliment Pharmacol Ther. 2015;42:1200–1210.CrossRefPubMed Jairath V, Khanna R, Zou GY et al. Development of Interim Patient-Reported Outcome Measures for the Assessment of Ulcerative Colitis Disease Activity in Clinical Trials. Aliment Pharmacol Ther. 2015;42:1200–1210.CrossRefPubMed
9.
Zurück zum Zitat Travis SP, Schnell D, Krzeski P et al. Developing an Instrument to Assess the Endoscopic Severity of Ulcerative Colitis: The Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61:535–542.CrossRefPubMed Travis SP, Schnell D, Krzeski P et al. Developing an Instrument to Assess the Endoscopic Severity of Ulcerative Colitis: The Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61:535–542.CrossRefPubMed
10.
Zurück zum Zitat Geboes K, Riddell R, Öst A, Jensfelt B, Persson T, Löfberg R. A Reproducible Grading Scale for Histological Assessment of Inflammation in Ulcerative Colitis. Gut. 2000;47:404–409.CrossRefPubMedPubMedCentral Geboes K, Riddell R, Öst A, Jensfelt B, Persson T, Löfberg R. A Reproducible Grading Scale for Histological Assessment of Inflammation in Ulcerative Colitis. Gut. 2000;47:404–409.CrossRefPubMedPubMedCentral
Metadaten
Titel
Correlations Between Gastrointestinal Symptoms and Endoscopic–Histologic Disease Activity in Adults with Ulcerative Colitis
verfasst von
Chung Sang Tse
Hang P. Nguyen
Siddharth Singh
Parambir S. Dulai
Jennifer Neill
Helen Le
Mark Valasek
Thierry Dervieux
Angelina E. Collins
Brigid Sweeney Boland
Publikationsdatum
03.06.2023
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 8/2023
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-023-07986-2

Weitere Artikel der Ausgabe 8/2023

Digestive Diseases and Sciences 8/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.